Company intelligence / Profile preview
RespireRx Pharmaceuticals
Glen Rock, New Jersey, USArespirerx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RespireRx has completed multiple Phase 1 safety trials and several Phase 2 proof-of-concept studies with its lead AMPAkine compounds demonstrating target engagement in antagonizing opioid-induced respiratory depression. Dronabinol has shown efficacy in reducing symptoms of obstructive sleep apnea in two completed Phase 2 trials. The company’s GABAkine KRM-II-81 has advanced to further preclinical evaluation within the NIH HEAL Initiative.
- Therapeutic areas
- PsychiatryPulmonologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Shirley Ryan AbilityLab (for SCI trial)Noramco Inc. (development of dronabinol)Cantheon Capital via ResolutionRx Ltd.
Beyond the preview
Go deeper on RespireRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RespireRx Pharmaceuticals.